Chartwell Investment Partners LLC Has $1.24 Million Stake in Aerie Pharmaceuticals, Inc. (AERI)

Chartwell Investment Partners LLC grew its position in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 3.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,591 shares of the company’s stock after acquiring an additional 791 shares during the period. Chartwell Investment Partners LLC owned about 0.07% of Aerie Pharmaceuticals worth $1,243,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Teachers Advisors LLC boosted its holdings in Aerie Pharmaceuticals by 5.1% during the first quarter. Teachers Advisors LLC now owns 49,726 shares of the company’s stock worth $2,255,000 after buying an additional 2,402 shares in the last quarter. California Public Employees Retirement System purchased a new stake in Aerie Pharmaceuticals during the first quarter worth about $231,000. Vanguard Group Inc. boosted its holdings in Aerie Pharmaceuticals by 7.1% during the first quarter. Vanguard Group Inc. now owns 1,392,525 shares of the company’s stock worth $63,151,000 after buying an additional 92,463 shares in the last quarter. BlackRock Inc. boosted its holdings in Aerie Pharmaceuticals by 113,376.8% during the first quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock worth $117,951,000 after buying an additional 2,598,596 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in Aerie Pharmaceuticals by 1.0% during the first quarter. Schwab Charles Investment Management Inc. now owns 136,106 shares of the company’s stock worth $6,173,000 after buying an additional 1,388 shares in the last quarter.

Aerie Pharmaceuticals, Inc. (AERI) opened at $61.30 on Monday. The company has a debt-to-equity ratio of 0.78, a current ratio of 15.24 and a quick ratio of 15.24. Aerie Pharmaceuticals, Inc. has a 52-week low of $35.20 and a 52-week high of $66.25.

A number of analysts recently commented on the stock. Needham & Company LLC reissued a “buy” rating and set a $65.00 price objective on shares of Aerie Pharmaceuticals in a report on Sunday, September 17th. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 24th. Mizuho restated a “buy” rating and set a $70.00 target price on shares of Aerie Pharmaceuticals in a research report on Wednesday, October 25th. Canaccord Genuity set a $65.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 16th. Finally, Guggenheim assumed coverage on shares of Aerie Pharmaceuticals in a research report on Monday, October 23rd. They set a “buy” rating and a $80.00 target price for the company. Two analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Aerie Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $71.43.

ILLEGAL ACTIVITY NOTICE: “Chartwell Investment Partners LLC Has $1.24 Million Stake in Aerie Pharmaceuticals, Inc. (AERI)” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://transcriptdaily.com/2017/11/27/chartwell-investment-partners-llc-has-1-24-million-stake-in-aerie-pharmaceuticals-inc-aeri.html.

Aerie Pharmaceuticals Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply